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Introduction {#jah32078-sec-0004}
============

Atrial fibrillation (AF) is a common cardiovascular complication associated to poor outcomes, including an increased risk of stroke. Anticoagulant therapy with warfarin can effectively reduce stroke risk by 60% at the cost, however, of an increased risk of intracranial hemorrhage (ICH) and bleeding.[1](#jah32078-bib-0001){ref-type="ref"} The success of preventing adverse events (both ischemic and bleeding events), with warfarin is dependent on maintaining an optimal anticoagulation management, namely, achieving international normalized ratio (INR) between 2.0 and 3.0. The time in therapeutic range (TTR) quantifies the percentage of time within this range, and optimal TTR has been associated with better outcomes.[2](#jah32078-bib-0002){ref-type="ref"} TTR is typically affected by patient‐related factors (including comorbidities and genetic predisposition), warfarin dose, drugs known to interact with warfarin, as well as center‐ and country/health care--related factors.[3](#jah32078-bib-0003){ref-type="ref"}, [4](#jah32078-bib-0004){ref-type="ref"}

Patients with chronic kidney disease (CKD) often develop AF. At the same time, CKD confers increased risk of ischemic stroke and bleeding.[5](#jah32078-bib-0005){ref-type="ref"}, [6](#jah32078-bib-0006){ref-type="ref"} Anticoagulation management in these patients is challenging, and some observational studies have raised concerns regarding the safety and effectiveness of warfarin in AF patients with CKD, particularly those with end‐stage renal disease and undergoing dialysis.[7](#jah32078-bib-0007){ref-type="ref"}, [8](#jah32078-bib-0008){ref-type="ref"} A limitation of those studies is, however, the lack of information on the patient\'s INR control, which could explain the observed increased risk of adverse outcomes in warfarin‐treated patients with CKD.

In this study, we hypothesized that patients with CKD have worse anticoagulant control (poor TTR), and that it is a worse TTR that associates with poor outcomes. We tested this hypothesis in a real‐world setting of newly diagnosed AF patients initiating warfarin therapy.

Methods {#jah32078-sec-0005}
=======

Study Population and Exposure {#jah32078-sec-0006}
-----------------------------

Patients were selected from the Stockholm CREatinine Measurements (SCREAM) project,[9](#jah32078-bib-0009){ref-type="ref"} a health care utilization cohort for the region of Stockholm, Sweden. SCREAM collected laboratory tests and health care use data from all individuals ≥18 years who had serum creatinine measured at least once between 2006 and 2011. SCREAM covers 98% of all cardiovascular disease cases registered in the region.[9](#jah32078-bib-0009){ref-type="ref"}

Eligible patients for this study were newly diagnosed AF patients initiating warfarin treatment (see Figure [1](#jah32078-fig-0001){ref-type="fig"}, flow chart). Diagnosis of AF and other comorbidities was obtained from International Classification of Diseases, Tenth Revision (ICD‐10) codes (see Tables [S1](#jah32078-sup-0001){ref-type="supplementary-material"} through [S4](#jah32078-sup-0001){ref-type="supplementary-material"} for definitions). AF has been shown to have a high diagnostic validity, with 95% having AF on electrocardiogram when based on ICD codes.[10](#jah32078-bib-0010){ref-type="ref"} Information on pharmacy‐dispensed medications was obtained from the Swedish Dispensed Drug registry, which records all dispensations from any Swedish pharmacy (Table [S2](#jah32078-sup-0001){ref-type="supplementary-material"}).

![Flow chart. INR, international normalized ratio.](JAH3-6-e004925-g001){#jah32078-fig-0001}

The index date was the day of the first warfarin dispensation after a new AF diagnosis. Demographics, comorbid history, and ongoing/recent medication (dispensations during the preceding 6 months) were calculated at that point. All available INR measurements from day 30 and up to 730 days (2 years) from the first warfarin purchase were used to estimate TTR. TTR was calculated as the percentage of time that INR was therapeutic (an INR between 2 and 3), assuming a linear association between 2 measurements.[11](#jah32078-bib-0011){ref-type="ref"} Patients were followed until INR measurements stopped (defined as lack of INR measurements within 60 days), occurrence of an adverse event (ICH/ischemic stroke/myocardial infarction \[MI\]/death), or 2 years from warfarin initiation.

The serum creatinine measured closest (within ±6 months) to index date was used to calculate eGFR by the Chronic Kidney Disease Epidemiology Collaboration formula,[12](#jah32078-bib-0012){ref-type="ref"} which is based on creatinine, age, sex, and race. All creatinines were isotope dilution mass spectrometry standardized, and renal function was categorized according to Kidney Disease: Improving Global Outcomes staging[13](#jah32078-bib-0013){ref-type="ref"} as follows: estimated glomerular filtration rate (eGFR) ≥60 mL/min per 1.73 m^2^, 45 to 59, 30 to 44, and \<30 or treated with dialysis. Patients undergoing dialysis were ascertained by linkage with the Swedish Renal Register. Given that albuminuria is less routinely measured in health care, differentiation of early CKD stages was not possible.

The requirement for informed consent was waived in this study. The study was approved by the local ethics committee in Stockholm, Sweden.

Outcome {#jah32078-sec-0007}
-------

The study outcome considered a composite of ICH, ischemic stroke, MI, or death. Events were ascertained through ICD‐10 codes (Table [S4](#jah32078-sup-0001){ref-type="supplementary-material"}) in connection with a health care consultation and by linkage with the Swedish Population registry, which records deaths and ICD‐10 causes of death for all Swedish citizens with no loss to follow‐up. The validity of ICH in the Swedish registry is very high at 99.4%.[14](#jah32078-bib-0014){ref-type="ref"} The validity of other ICD diagnoses derived from the patient register is between 85% and 95%.[15](#jah32078-bib-0015){ref-type="ref"} Events were included if occurring within 30 days from the last INR measurement (30‐day lag phase).

Statistical Analysis {#jah32078-sec-0008}
--------------------

Continuous data are presented as mean (±SD) or median (interquartile interval; IQR). Categorical data are presented as number and percentage. Fractional regression analysis was used to assess whether eGFR and CKD stages associated with TTR. Analyses were adjusted for clinically relevant factors and factors reported to be associated with TTR in previous studies.[3](#jah32078-bib-0003){ref-type="ref"}, [16](#jah32078-bib-0016){ref-type="ref"} These were: age (in categories: \<65, 65--74, 75--85, and ≥85 years), sex, diabetes mellitus, liver disease, hypertension, vascular disease, heart failure, valvular disease, amiodarone use, aspirin use, cancer, and renal function (as 4 eGFR categories eGFR ≥60, 45--59, 30--44, and \<30/dialysis).

The association between TTR, renal function, and adverse outcomes was assessed in a logistic regression model. Covariates included renal function categories (same as above), TTR (categories \>75, 60--75, and \<60%), age (\<65, 65--74, 75--84, and ≥85 years), sex, diabetes mellitus, hypertension, vascular disease, heart failure, valvular disease, cancer, known coagulation/platelet defect, anemia, past ischemic stroke, past venous thromboembolism, past intracranial bleeding, past gastrointestinal bleeding, antiplatelet use, number of INR measurements, and number of days on warfarin. Interactions were tested between renal function and TTR, renal function and age, and age and TTR.

As a sensitivity analysis, we recomputed TTR using only INR measurements during the first 180 days (3 months) of therapy (Figure [1](#jah32078-fig-0001){ref-type="fig"}) and then estimated time‐to‐event from day 180 onward. In this setting, we followed patients for up to 2 years regardless of whether warfarin was discontinued. A Kaplan--Meier curve was used to graphically display the unadjusted association between an adverse outcome and TTR. A multivariable Cox regression analysis assessed the association between renal function, TTR, and the composite outcome. Covariates included the same as mentioned above. The proportional hazards assumption for the Cox model was tested with the Schoenfeld residuals, and overall fit of the Cox model was evaluated by plotting the Cox‐Snell residuals. All analyses were performed using STATA software (version 14.1; StataCorp LP, College Station, TX).

Results {#jah32078-sec-0009}
=======

Study Population {#jah32078-sec-0010}
----------------

Between 2006 and 2011, 11 064 new AF cases were registered in the region of Stockholm. Of those, 7738 patients initiated warfarin treatment and had a recent creatinine measured to estimate their eGFR (Figure [1](#jah32078-fig-0001){ref-type="fig"}, Table [1](#jah32078-tbl-0001){ref-type="table-wrap"}). The median TTR (IQR) was 83% (71--92). The median eGFR was 73 (59--86) mL/min per 1.73 m^2^. There were 11 patients treated with dialysis.

###### 

Baseline Characteristics of Study Participants

                                          All            eGFR ≥60       eGFR 45 to 59   eGFR 30 to 44   eGFR \<30 or Dialysis   *P* Value
  --------------------------------------- -------------- -------------- --------------- --------------- ----------------------- -----------
  N                                       7738           5692           1353            512             181                     
  eGFR, median (IQR)                      73 (59--86)    80 (71--89)    54 (50--57)     39 (36--42)     23 (15--27)             
  Age, median (IQR), y                    73 (65--80)    70 (63--78)    78 (72--83)     81 (76--85)     80 (71--85)             \<0.001
  \<65                                    2006 (25.9%)   1846 (32.4%)   108 (8.0%)      30 (5.9%)       22 (12.2%)              \<0.001
  65 to 74                                2461 (31.8%)   1953 (34.3%)   382 (28.2%)     88 (17.2%)      38 (21.0%)              
  75 to 84                                2565 (33.1%)   1603 (28.2%)   631 (46.6%)     253 (49.4%)     78 (43.1%)              
  ≥85                                     706 (9.1%)     290 (5.1%)     232 (17.1%)     141 (27.5%)     43 (23.8%)              
  Female                                  3153 (40.7%)   2112 (37.1%)   676 (50.0%)     273 (53.3%)     92 (50.8%)              \<0.001
  CHA~2~DS~2~‐VASc, mean (SD)             2.9 (1.8)      2.6 (1.8)      3.7 (1.6)       4.4 (1.6)       4.2 (1.7)               \<0.001
  HAS‐BLED, mean (SD)                     2.1 (1.1)      1.9 (1.1)      2.4 (1.0)       2.6 (0.9)       3.1 (1.0)               \<0.001
  Comorbid history                                                                                                              
  MI                                      690 (8.9%)     402 (7.1%)     146 (10.8%)     105 (20.5%)     37 (20.4%)              \<0.001
  Ischemic heart disease                  1423 (18.4%)   892 (15.7%)    309 (22.8%)     168 (32.8%)     54 (29.8%)              \<0.001
  Peripheral arterial disease             382 (4.9%)     227 (4.0%)     83 (6.1%)       49 (9.6%)       23 (12.7%)              \<0.001
  PCI                                     216 (2.8%)     134 (2.4%)     48 (3.5%)       31 (6.1%)       3 (1.7%)                \<0.001
  CABG                                    112 (1.4%)     73 (1.3%)      26 (1.9%)       12 (2.3%)       1 (0.6%)                0.068
  Hypertension                            4014 (51.9%)   2693 (47.3%)   820 (60.6%)     364 (71.1%)     137 (75.7%)             \<0.001
  Diabetes mellitus                       1153 (14.9%)   741 (13.0%)    241 (17.8%)     122 (23.8%)     49 (27.1%)              \<0.001
  Heart failure                           716 (9.3%)     315 (5.5%)     203 (15.0%)     137 (26.8%)     61 (33.7%)              \<0.001
  Valvular disease                        94 (1.2%)      60 (1.1%)      18 (1.3%)       11 (2.1%)       5 (2.8%)                0.033
  Biological valve prosthesis             43 (0.6%)      25 (0.4%)      9 (0.7%)        6 (1.2%)        3 (1.7%)                0.027
  Mechanical valve prosthesis             65 (0.8%)      38 (0.7%)      17 (1.3%)       7 (1.4%)        3 (1.7%)                0.046
  Pacemaker/ICD                           367 (4.7%)     226 (4.0%)     80 (5.9%)       47 (9.2%)       14 (7.7%)               \<0.001
  Known liver disease                     31 (0.4%)      23 (0.4%)      2 (0.1%)        3 (0.6%)        3 (1.7%)                0.021
  Chronic obstructive pulmonary disease   489 (6.3%)     332 (5.8%)     95 (7.0%)       46 (9.0%)       16 (8.8%)               0.009
  Cancer (within last 3 years)            971 (12.5%)    631 (11.1%)    211 (15.6%)     94 (18.4%)      35 (19.3%)              \<0.001
  Alcohol abuse                           151 (2.0%)     123 (2.2%)     16 (1.2%)       7 (1.4%)        5 (2.8%)                0.071
  Dementia                                33 (0.4%)      17 (0.3%)      10 (0.7%)       6 (1.2%)        0 (0.0%)                0.005
  Gastrointestinal bleeding               124 (1.6%)     85 (1.5%)      23 (1.7%)       9 (1.8%)        7 (3.9%)                0.091
  Known coagulation/platelet defect       58 (0.7%)      37 (0.7%)      13 (1.0%)       6 (1.2%)        2 (1.1%)                \<0.001
  Known anemia                            311 (4.0%)     178 (3.1%)     65 (4.8%)       41 (8.0%)       27 (14.9%)              \<0.001
  Ischemic stroke                         616 (8.0%)     421 (7.4%)     122 (9.0%)      59 (11.5%)      14 (7.7%)               0.004
  Transient ischemic attack               289 (3.7%)     201 (3.5%)     55 (4.1%)       27 (5.3%)       6 (3.3%)                0.21
  Peripheral systemic embolism            66 (0.9%)      31 (0.5%)      15 (1.1%)       15 (2.9%)       5 (2.8%)                \<0.001
  Pulmonary embolism                      308 (4.0%)     191 (3.4%)     64 (4.7%)       38 (7.4%)       15 (8.3%)               \<0.001
  Deep venous thrombosis                  191 (2.5%)     138 (2.4%)     30 (2.2%)       19 (3.7%)       4 (2.2%)                0.29
  Medication history (last 6 months)                                                                                            
  Aspirin                                 2782 (36.0%)   1870 (32.9%)   598 (44.2%)     241 (47.1%)     73 (40.3%)              \<0.001
  Clopidogrel                             158 (2.0%)     94 (1.7%)      34 (2.5%)       24 (4.7%)       6 (3.3%)                \<0.001
  NSAID                                   1250 (16.2%)   908 (16.0%)    217 (16.0%)     94 (18.4%)      31 (17.1%)              0.54
  Acetaminophen                           971 (12.5%)    642 (11.3%)    185 (13.7%)     99 (19.3%)      45 (24.9%)              \<0.001
  Statins                                 1927 (24.9%)   1299 (22.8%)   395 (29.2%)     176 (34.4%)     57 (31.5%)              \<0.001
  SSRI                                    337 (4.4%)     233 (4.1%)     71 (5.2%)       25 (4.9%)       8 (4.4%)                0.28
  Proton pump inhibitor                   1023 (13.2%)   666 (11.7%)    212 (15.7%)     104 (20.3%)     41 (22.7%)              \<0.001
  Amiodarone                              12 (0.2%)      8 (0.1%)       2 (0.1%)        1 (0.2%)        1 (0.6%)                0.58
  Macrolides                              52 (0.7%)      33 (0.6%)      12 (0.9%)       2 (0.4%)        5 (2.8%)                0.003
  Quinolones                              260 (3.4%)     171 (3.0%)     54 (4.0%)       22 (4.3%)       13 (7.2%)               0.004
  Cotrimoxazole                           24 (0.3%)      17 (0.3%)      4 (0.3%)        0 (0.0%)        3 (1.7%)                0.007

Data are presented as n (%), median (IQR) or mean (SD). CABG indicates coronary artery bypass graft; ICD, intracardiac defibrillator; IQR, interquartile range; MI, myocardial infarction; NSAID, nonsteroidal anti‐inflammatory drugs; PCI, percutaneous coronary intervention; SSRI, selective serotonin reuptake inhibitors.

As compared to patients with normal renal function (eGFR ≥60 mL/min per 1.73 m^2^), those within CKD were older. Across lower eGFR strata, there was a higher proportion of women and a more‐frequent history of hypertension and MI. Both the CHA~2~DS~2~‐VASC and HAS‐BLED scores were higher. Patients with lower eGFR categories more often used medications that could increase the risk of bleeding (eg, aspirin or a combined antiplatelet therapy; Table [1](#jah32078-tbl-0001){ref-type="table-wrap"}) or drugs known to interact with warfarin (ie, antibiotics).

eGFR Strata and TTR {#jah32078-sec-0011}
-------------------

TTR was poorer across lower eGFR strata (Figure [2](#jah32078-fig-0002){ref-type="fig"}, Table [2](#jah32078-tbl-0002){ref-type="table-wrap"}). This association remained after multivariable adjustment (Figure [3](#jah32078-fig-0003){ref-type="fig"}, Table [3](#jah32078-tbl-0003){ref-type="table-wrap"}). As shown in Table [3](#jah32078-tbl-0003){ref-type="table-wrap"}, patients with eGFR of 45 to 59 had mean predicted TTR of 79%, which, albeit significantly (*P*\<0.05) lower than the reference category (eGFR ≥60), was only 1% higher (95% CI, 0--25). Patients with eGFR of 30 to 44 had mean predicted TTR of 77%, which was 1% lower (95% CI, −3 to −10; *P*=0.3) than the reference category. On the other hand, patients with an eGFR \<30/dialysis had a mean predicted TTR of 68% (95% CI, 65--72), which was 10% lower than the reference category. The fully adjusted multivariable model is shown in Table [4](#jah32078-tbl-0004){ref-type="table-wrap"}. Other covariates independently associated with worse TTR were, besides eGFR strata, female sex (weak association), higher age (weak association), presence of diabetes mellitus, vascular disease, or heart failure, and concomitant use of aspirin (Table [4](#jah32078-tbl-0004){ref-type="table-wrap"}).

![Proportion of patients in different time‐in‐therapeutic ranges (TTR) across worsening eGFR strata. eGFR indicates estimated glomerular filtration rate.](JAH3-6-e004925-g002){#jah32078-fig-0002}

###### 

TTR Across eGFR Strata

                                             All             eGFR ≥60        eGFR 45 to 59   eGFR 30 to 44   eGFR \<30 or Dialysis   *P* Value
  ------------------------------------------ --------------- --------------- --------------- --------------- ----------------------- -----------
  N                                          7738            5692            1353            512             181                     
  TTR %, median (IQR)                        83 (71--92)     83 (71--92)     83 (72--91)     82 (68--90)     70 (50--82)             \<0.001
  TTR %, mean (SD)                           78 (20)         78 (20)         79 (19)         76 (21)         66 (23)                 \<0.001
  TTR in categories                                                                                                                  
  TTR \>75%, n (%)                           5204 (67.3)     3853 (67.7)     951 (70.3)      324 (63.3)      76 (42.0)               \<0.001
  TTR 60% to 75%, n (%)                      1423 (18.4)     1042 (18.3)     248 (18.3)      94 (18.4)       39 (21.5)               
  TTR \<60%, n (%)                           1111 (14.4)     797 (14.0)      154 (11.4)      94 (18.4)       66 (36.5)               
  Number of INR measurements, median (IQR)   21 (9--39)      20 (9--38)      25 (10--41)     24 (11--42)     21 (9--43)              \<0.001
  Median (IQR) days on warfarin              254 (91--691)   244 (91--671)   329 (99--708)   287 (96--704)   175 (57--589)           \<0.001
  Median (IQR) days between INRs             12 (8--17)      12 (8--17)      13 (8--17)      12 (8--16)      9 (5--14)               \<0.001
  Percent (IQR) of INRs \>3.0                11% (0--19)     11 (0--19)      12 (3.7--20)    13 (5.8--21)    14 (6.5--23)            \<0.001
  Percent (IQR) of INRs \<2.0                19% (9--31)     18 (9--30)      19 (10--30)     20 (10--31)     29 (18--43)             \<0.001

IQR indicates interquartile range; INRs, international normalized ratios; TTR, time‐in‐therapeutic range.

![Adjusted mean predictions of time‐in‐therapeutic range (TTR) with 95% confidence intervals in 4 eGFR strata. Output from a multivariable fractional regression analysis including eGFR strata, age (in categories: \<65, 65--74, 75--85, and ≥85 years), sex, diabetes mellitus, liver disease, hypertension, vascular disease, heart failure, valvular disease, amiodarone use, aspirin use, and cancer. eGFR indicates estimated glomerular filtration rate.](JAH3-6-e004925-g003){#jah32078-fig-0003}

###### 

Predictors of TTR

  CKD Stage[a](#jah32078-note-0005){ref-type="fn"} (mL/min per 1.73 m^2^)   TTR (95% CI)   *P* Value   Change in TTR (95% CI)   *P* Value
  ------------------------------------------------------------------------- -------------- ----------- ------------------------ -----------
  ≥60                                                                       78% (77--79)   \<0.001     (Ref)                    ···
  45 to 59                                                                  79% (78--80)   \<0.001     1% (0--25)               0.033
  30 to 44                                                                  77% (75--79)   \<0.001     −1% (−3 to 10)           0.313
  \<30 or dialysis                                                          68% (65--72)   \<0.001     −10% (−13 to −60)        \<0.001

Simplified fractional regression analysis showing the mean predicted TTR across renal function categories and the relative change (in proportion) from the reference category.

Fractional regression analysis adjusted for: age (in categories: \<65, 65--74, 75--85, ≥85 years), sex, diabetes mellitus, liver disease, hypertension, vascular disease (myocardial infarction, ischemic heart disease, peripheral arterial disease), heart failure, valvular disease, amiodarone use, aspirin use, and cancer. CKD indicates chronic kidney disease; TTR, time‐in‐therapeutic range.

###### 

Full Fractional Regression Analysis Showing the Coefficients (and 95% Confidence Intervals) of All Available Covariates Considered to Influence TTR

  Predictors of TTR                                                                 Coefficient (95% CI)      *P* Value
  --------------------------------------------------------------------------------- ------------------------- -----------
  Renal function categories                                                                                   
  eGFR ≥60                                                                          Ref                       
  eGFR 45 to 59                                                                     7.6% (0.5--14.7)          0.035
  eGFR 30 to 44                                                                     −5.9% (−17.3 to 5.4)      0.307
  eGFR \<30 or dialysis                                                             −50.1% (−65.5 to −34.6)   \<0.001
  Age, y                                                                                                      
  Age \<65                                                                          Ref                       
  Age 65 to 74                                                                      7.7% (0.6--14.7)          0.034
  Age 75 to 84                                                                      3.1% (−4.2 to 10.5)       0.404
  Age ≥85                                                                           −2.4% (−13.3 to 8.6)      0.671
  Women                                                                             −5.3% (−10.8 to 1.8)      0.058
  Diabetes mellitus                                                                 −13.2% (−20.6 to − 5.8)   \<0.001
  Liver disease                                                                     −21.9% (−66.0 to 22.2)    0.330
  Hypertension                                                                      1.5% (−4.0 to 7.0)        0.596
  Vascular disease (past MI, ischemic heart disease, peripheral arterial disease)   −10.5 (−18.5 to −2.5)     0.010
  Heart failure                                                                     −17.1% (−26.4 to −7.7)    \<0.001
  Valvular disease                                                                  4.4% (−19.3 to 28.0)      0.717
  Amiodarone                                                                        −35.9% (−111 to 39.6)     0.351
  Aspirin                                                                           6.3% (5.4--11.9)          0.032
  Cancer within last 3 years                                                        −4.9% (−12.8 to 3.0)      0.226

eGFR indicates estimated glomerular filtration rate; MI, myocardial infarction; TTR, time‐in‐therapeutic range.

TTR, eGFR Strata, and Risk of Adverse Outcomes {#jah32078-sec-0012}
----------------------------------------------

A total of 402 (5.1%) adverse events occurred during 254 days (IQR, 91--691; Table [5](#jah32078-tbl-0005){ref-type="table-wrap"}). The most common adverse event was death (2.6%), followed by ischemic stroke (1.7%), ICH (0.5%), and MI (0.4%). In adjusted logistic regression analyses, both renal function and TTR were independently associated with the odds of adverse events (Table [6](#jah32078-tbl-0006){ref-type="table-wrap"}). The association between TTR and adverse events was not modified by differing eGFR (*P* for interaction, 0.169). Patients with TTR 60% to 75% (odds ratio \[OR\], 1.84; 95% CI, 1.41--2.40) and TTR \<60% (OR, 2.09; CI, 1.59--2.74) had higher odds of adverse events than patients with TTR \>75%.

###### 

Proportion of Survivors as Well as Single and Composite Study Outcomes Across eGFR Strata

                                 eGFR ≥60     eGFR 45 to 59   eGFR 30 to 44   eGFR \<30 or Dialysis   *P* Value
  ------------------------------ ------------ --------------- --------------- ----------------------- -----------
  N                              5692         1353            512             181                     
  Single endpoints                                                                                    
  ICH                            26 (0.5%)    9 (0.7%)        2 (0.4%)        2 (1.1%)                \<0.001
  Ischemic stroke                86 (1.5%)    31 (2.3%)       11 (2.2%)       5 (2.8%)                
  MI                             12 (0.2%)    10 (0.7%)       9 (1.8%)        1 (0.6%)                
  Death                          102 (1.8%)   42 (3.1%)       33 (6.5%)       21 (11.6%)              
  Combined endpoint                                                                                   
  ICH/ischemic stroke/MI/death   226 (4.0%)   92 (6.8%)       55 (10.7%)      29 (16.0%)              \<0.001

Data presented as n (%). eGFR indicates estimated glomerular filtration rate; ICH, intractranial hemorrhage; MI, myocardial infarction.

###### 

Multivariable Logistic Regression of Factors Associated With the Composite Endpoint of ICH, Ischemic Stroke, MI, and Death (n=7738) for All Included Patients

                                                                                       OR (95% CI)         *P* Value
  ------------------------------------------------------------------------------------ ------------------- -----------
  Renal function, mL/min per 1.73 m^2^                                                                     
  eGFR ≥60                                                                             1.0 (ref)           
  eGFR 45 to 59                                                                        1.32 (1.01--1.72)   0.045
  eGFR 30 to 44                                                                        1.54 (1.09--2.18)   0.025
  eGFR \<30, or dialysis                                                               1.70 (1.06--2.72)   0.27
  TTR                                                                                                      
  TTR \>75%                                                                            1.0 (ref)           
  TTR 60% to 75%                                                                       1.84 (1.41--2.40)   \<0.001
  TTR \<60%                                                                            2.09 (1.59--2.74)   \<0.001
  Age, y                                                                                                   
  \<65                                                                                 1.0 (ref)           
  65 to 74                                                                             2.03 (1.41--2.92)   \<0.001
  75 to 84                                                                             3.40 (2.38--4.87)   \<0.001
  ≥85                                                                                  3.14 (2.02--4.89)   \<0.001
  Female                                                                               0.92 (0.74--1.14)   0.427
  Diabetes mellitus                                                                    1.08 (0.82--1.43)   0.574
  Hypertension                                                                         0.96 (0.77--1.21)   0.740
  Vascular disease (past MI, ischemic heart disease, or peripheral arterial disease)   1.40 (1.06--1.83)   0.017
  Heart failure                                                                        1.78 (1.33--2.36)   \<0.001
  Valvular disease                                                                     1.27 (0.59--2.75)   0.542
  Cancer within last 3 years                                                           0.85 (0.62--1.15)   0.292
  Coagulation/platelet defect                                                          3.06 (1.33--7.07)   0.009
  Anemia                                                                               1.10 (0.71--1.69)   0.681
  Ischemic stroke                                                                      0.71 (0.43--1.20)   0.200
  Past systemic emboli                                                                 1.70 (1.13--2.54)   0.010
  Deep vein thrombosis/pulmonary embolism                                              1.51 (1.05--2.16)   0.025
  Past ICH                                                                             1.12 (0.29--4.35)   0.865
  Past gastrointestinal bleeding                                                       1.37 (0.70--2.68)   0.356
  Antiplatelet therapy                                                                 1.07 (0.85--1.35)   0.543
  No. of INR measurements                                                              1.03 (1.02--1.04)   \<0.001
  No. of days on warfarin                                                              1.00 (0.99--1.00)   \<0.001

*P* values for the interaction terms for the outcome is presented below the table. Interaction terms tested: age and eGFR: *P*=0.398; age and TTR, *P*=0.721; eGFR and TTR, *P*=0.169. eGFR indicates estimated glomerular filtration rate; ICH, intractranial hemorrhage; INR, international normalized ratio; MI, myocardial infarction; TTR, time‐in‐therapeutic range.

Sensitivity Analyses {#jah32078-sec-0013}
--------------------

There were 7577 (98%) event‐free patients during the first 3 months of warfarin therapy (Figure [1](#jah32078-fig-0001){ref-type="fig"}). Survival is graphically displayed after the first 3 months according to TTR strata (Figure [S1](#jah32078-sup-0001){ref-type="supplementary-material"}) and in relation to renal function (Figure [S2](#jah32078-sup-0001){ref-type="supplementary-material"}). We estimated TTR from the first 3 months of INR measurement (Table [S5](#jah32078-sup-0001){ref-type="supplementary-material"}) and modeled time to event from month 3 onward by Cox proportional models without censoring at warfarin cessation. During follow‐up, 683 patients (9.0%) had an event (Table [S6](#jah32078-sup-0001){ref-type="supplementary-material"}). In adjusted Cox regression analysis (Table [S7](#jah32078-sup-0001){ref-type="supplementary-material"}), both a lower TTR and a lower renal function predicted adverse outcomes, with no interaction terms (*P* for interaction=0.8). Patients with TTR 60% to 75% (hazard ratio \[HR\], 1.52; CI, 1.25--1.83) and with TTR \<60% (HR, 1.89; CI, 1.58--2.25) had a 52% and 89% higher risk of adverse events, respectively, as compared with a TTR \>75%.

Discussion {#jah32078-sec-0014}
==========

This study shows a clinically relevant association between renal dysfunction and poor TTR among new AF patients on warfarin. An adequate TTR was less frequently achieved in CKD patients, especially among those with severe CKD. This study also shows that fewer adverse events are observed in patients with adequate TTR, irrespective of underlying renal function.

TTR is a measure of long‐term INR control, which is frequently used in clinical trials and recommended by current National Institute for Health and Care Excellence guidelines.[17](#jah32078-bib-0017){ref-type="ref"} However, we acknowledge that it is probably still rarely used in clinical practice. TTR gives a percentage of time of the treatment period that the INR was therapeutic, but it does not tell whether values were sub‐ or supratherapeutic. Adverse events are closely related to achieved TTR, with an optimal threshold of TTR somewhere above 58% to 65%.[2](#jah32078-bib-0002){ref-type="ref"}, [17](#jah32078-bib-0017){ref-type="ref"}, [18](#jah32078-bib-0018){ref-type="ref"}, [19](#jah32078-bib-0019){ref-type="ref"}, [20](#jah32078-bib-0020){ref-type="ref"} In our study, the observed TTR was exceptionally high, in accord with Sweden\'s renowned good INR control (with a mean over 75% in several randomized, controlled, clinical trials[18](#jah32078-bib-0018){ref-type="ref"}, [19](#jah32078-bib-0019){ref-type="ref"}). Yet, our study did observe that despite extensive adjustment for confounders, those with eGFR \<30/dialysis had a clinically worse TTR. The reasons behind the worse TTR in CKD patients cannot be inferred from our observational design, but may be attributed to renal function per se, as well as factors/conditions associated with CKD. It is notable that patients with severe CKD had more‐frequent INR measurements, possibly attributed to difficulties in achieving optimal INR, more‐frequent therapy discontinuations attributed to procedures/intervention, or by the more‐frequent use of drugs known to interact with warfarin. Our study expands to a real‐life North European setting the series of studies from Limdi et al, showing, in the US Warfarin Pharmacogenetics Cohort, that patients with CKD not requiring dialysis require lower warfarin doses, more often had supratherapeutic INRs (INR ≥4), and have a higher risk of hemorrhage, as compared to patients with normal kidney function.[7](#jah32078-bib-0007){ref-type="ref"}, [21](#jah32078-bib-0021){ref-type="ref"}, [22](#jah32078-bib-0022){ref-type="ref"}, [23](#jah32078-bib-0023){ref-type="ref"} The difficulty of CKD patients in keeping optimal INR was also reported by Quinn et al[24](#jah32078-bib-0024){ref-type="ref"} in 46 US dialysis patients with weekly INR measurements and an achieved mean TTR of 49.2%.

There is strong evidence that the risk of ischemic stroke caused by AF can be substantially reduced with adequate warfarin therapy. Subtherapeutic INR (below 2.0) increases the risk of ischemic stroke, and supratherapeutic INR (above 3.0 and particularly above 4.0) sharply increases the risk of intracranial bleeding.[25](#jah32078-bib-0025){ref-type="ref"} A recent study indicated that ICH risk associated with INR ≥4.0 increased by several fold in individuals with advanced CKD.[7](#jah32078-bib-0007){ref-type="ref"} In most reports, as well as in our study, subtherapeutic INRs (19% of measurements) were more common than supratherapeutic ones (11%). We speculated that poor TTR may, in part, explain the worse outcome and higher bleeding rate described in observational studies of CKD patients on warfarin, particularly among those undergoing dialysis.[26](#jah32078-bib-0026){ref-type="ref"}, [27](#jah32078-bib-0027){ref-type="ref"} We observed no interaction between TTR and eGFR and outcome in our study, suggesting that both factors affect outcome independently of each other, and that adequate TTR reduces the adverse event risk also in patients with advanced CKD/dialysis. Despite being the largest study of its kind, we could only identify 11 patients on dialysis satisfying inclusion criteria, and we are therefore underpowered to report TTR‐associated outcomes in this particular population. However, our findings accord with an earlier small, retrospective study indicating that no dialysis patient with adequate INR control had a stroke or a fatal bleeding event.[28](#jah32078-bib-0028){ref-type="ref"} Further, Kooiman et al[29](#jah32078-bib-0029){ref-type="ref"} observed that both less time spent within therapeutic range and high INR variability were factors associated with increased risk of stroke and bleeding in warfarin‐treated CKD patients. Within our study design, we were concerned that patients who were critically ill/moribund would be taken off warfarin and died shortly after warfarin discontinuation. For that reason, our sensitivity analysis estimated TTR on the first 3 months and analyzed outcome risk emulating an "intention to treat" design. The fact that results were comparable to our main analysis provides robustness to our conclusions.

Strengths of this study are the large real‐life cohort with information on INR control and eGFR. In addition, the inclusion of newly diagnosed AF patients with complete information on warfarin therapy and outcomes provides more‐unbiased associations. However, this study also has limitations: Our analysis is based on repeated warfarin dispensations, but we lack information on short‐term therapy discontinuations or indications for it. This probably would have prompted the physician to order more INR measurements during that period of time, but likely in the long term would have less effect on TTR. Finally, we only accounted for comorbidities and drugs interacting with warfarin at index date, but not during follow‐up. In the multivariable fractional regression analysis, we have included all available variables. However, there could still be residual confounding, given that unmeasured factors associated with a worse TTR are not accounted for. However, it is unknown whether renal function is associated with additional harmful factors.

Conclusion {#jah32078-sec-0015}
==========

In real‐life newly diagnosed AF patients on warfarin, those with eGFR \<30/dialysis have a significantly worse INR control. An optimal TTR (\>75%) is associated with lower risk of adverse events, independently of underlying renal function. Identifying the reasons behind, and applying more‐stringent efforts to improve, the TTR of these patients is necessary to ensure warfarin\'s net clinical benefit.
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**Figure S1.** Sensitivity analysis: association of TTR and renal function to outcome. Kaplan--Meier curve: time‐in‐therapeutic range and association to outcome. Outcome is a composite of intracranial hemorrhage/ischemic stroke/myocardial infarction/death.
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